Adamis acquires prostrate drug candidates from Colby Pharmaceuticals Adamis Pharmaceuticals Company.

Dennis J. Carlo, President and CEO of Adamis stated Another few months should be a thrilling time for Adamis; some of the near term milestones shall include submitting the IND for APC-100 Stage I/IIa prostate malignancy clinical trial, submitting an IND for a Phase II telomerase cancers vaccine clinical trial, start manufacturing of our second prostate medication APC-200 and publication and announcement of the Stage III efficacy outcomes of our C31G contraception product.. Adamis acquires prostrate drug candidates from Colby Pharmaceuticals Adamis Pharmaceuticals Company , today announced the completion of the acquisition from Colby Pharmaceuticals of the rest of the exclusive license agreements relating to two drug product candidates for the treating prostate malignancy .Axiom Custom Genotyping Arrays enable them to do this with an array of formats, relevant articles, and high-quality data to expedite their disease association studies.’.. AMRI first-quarter total income down 9 percent to $49.3 million AMRI today reported financial and operating outcomes for the first one fourth ended March 31, 2010. In U.K. To expand geographic service offering in our Development and Huge Scale business components First Quarter 2010 Outcomes Total revenue for the first quarter of 2010 was $49.3 million, a decrease of 9 percent compared to total revenue of $54.0 million reported in the initial quarter of 2009. Total contract income for the first quarter of 2010 was $38.9 million, a loss of 10 percent in comparison to total contract revenue of $43.2 million reported in ’09 2009.